Hunan Siweikang Therapeutics

Hunan Siweikang Therapeutics is a clinical-stage biotechnology company headquartered in Changsha, China, specializing in the development of next-generation chimeric antigen receptor (CAR) T-cell therapies. Founded in 2018 by Dr. Biliang Hu, a former researcher in the laboratory of CAR-T pioneer Dr. Carl June, the company focuses on "fourth-generation" cell therapies designed to improve safety and efficacy through multi-targeting and integrated cytokine regulation. Its lead program, SCAR-02, is a bispecific CAR-T targeting BCMA and CD19, currently being evaluated in Phase 2 clinical trials for autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus. Beyond its oncology and autoimmune pipelines, the company maintains a strategic partnership with Truking Technology to develop automated manufacturing solutions for cell and gene therapies. Siweikang is a pioneer in applying CAR-T technology to refractory autoimmune conditions, aiming to provide curative-intent treatments for patients who have failed conventional therapies.